A Study of Efbemalenograstim Alfa Injection for Stage IIIB or IV NSCLC Recieving Moderate-risk Febrile Neutropenia (FN) Chemotherapy Regimen With Risk Factors
Conditions
- Non Small Cell Lung Cancer
Interventions
- DRUG: Efgbemalenograstim alfa
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Collaborators